HighTower Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
Other funds holding TARS
HighTower Advisors's TARS Position: Q3 2026 in Review
HighTower Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 0.26% in Q3 2026, buying an estimated $625 and bringing the position to 3,419 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #3301.
HighTower Advisors first reported a position in TARS in Q4 2024 and has held it in 6 quarters since. The position peaked at $297K in Q4 2025. 200 funds tracked by Wall St. Rank hold TARS as of Q3 2026.
- HighTower Advisors held 3,419 shares of Tarsus Pharmaceuticals worth $269K as of Q3 2026.
- HighTower Advisors bought 9 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $625.
- Tarsus Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3301 holding.
- HighTower Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
- HighTower Advisors's Tarsus Pharmaceuticals position peaked at $297K in Q4 2025.
- 200 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.
Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.